The purpose of the study was to determine the role of E-cadherin in the development and progression of molecular subtypes of invasive ductal breast cancer by assessing the expression of E-cadherin in various clinical and pathological prognostic parameters. Materials and methods. We demonstrated a comprehensive morphological, including immunohistochemical study of 193 cases of invasive ductal breast cancer with the molecular phenotype definition. General histological processing of samples was performed according to standard methods. Immunohistochemical studies for E-cadherin, ER, PR, c-erbB2, Ki-67 were performed according to standardized analytically validated protocols with the necessary controls. The grade of malignancy was determined according to the modified scheme of P. Scarff, H. Bloom and W. Richardson. E-cadherin expression level was quantified in 86 observations using the Qureshi counting system. Comparison of E-cadherin expression in different clinical and pathological parameters was evaluated using Pearson's test χ2. For all types of analysis, differences were considered significant at p <0.05. Results and discussion. E-cadherin expression in ductal breast cancer tissue is significantly lower in cases with lymph node metastases than without metastatic lymph node involvement (χ2 = 4.55, p = 0.031). Low expression of E-cadherin or its absence was associated with pT3 tumors, clinical stage 3, with G2 and G3 malignancies. Loss of E-cadherin expression has an unfavorable prognostic value. E-cadherin expression is associated with the molecular type of invasive breast ductal carcinoma. High E-cadherin expression was common in ER-positive tumors of the luminal A phenotype and was determined in patients of both premenopausal and postmenopausal age, suggesting that ER-positive expression may be involved in the regulation of E-cadherin expression. Low tumor activity of cells of invasive ductal breast cancer of the luminal subtype is accompanied by an increase in the adhesive properties of these cells due to the high level of expression of E-cadherin. E-cadherin is considered an independent marker of triple-negative breast cancer and is characterized by an unfavorable prognosis and short life expectancy. Triple-negative cancer was associated with a significant predominance of patients with low and negative E-cadherin expression (p = 0.011). Conclusion. Thus, E-cadherin is a potent tumor suppressor of breast cancer. According to this role in the progression of breast cancer, it was found that partial or complete loss of E-cadherin expression correlates with an unfavorable prognosis in patients

Keywords: invasive ductal breast cancer, E-cadherin expression, prognosis

Full text: PDF (Ukr) 620K

1. WHO. Breast cancer. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer
2. Volos LI, Dudash AP. Invasive ductal breast carcinoma: morphological features of molecular subtypes. Medical University of Lublin, 2021.The modern stage of the development of medical education in Ukraine and EU countries: Collective monograph. Riga, Latvia: "Baltija Publishing"; 2021. p. 50-66. https://doi.org/10.30525/978-9934-26-090-2-3
3. Fernández-Tortolero Á, Reigosa-Yániz A. Subtypes of luminal breast carcinoma according to the Saint Gallen Consensus in a group of Venezuelan patients. Biomedica. 2021 Sep 22;41(3):531-40. PMID: 34559498 PMCID: PMC8519592. https://doi.org/10.7705/biomedica.5496
4. Ignatiadis M, Sotiriou C. Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol. 2013 Sep;10(9):494-506. PMID: 23881035. https://doi.org/10.1038/nrclinonc.2013.124
5. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84. https://doi.org/10.1016/S0140-6736(11)60993-8
6. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717. PMID: 15894097. https://doi.org/10.1016/S0140-6736(05)66544-0
7. Erić I, Petek Erić A, Kristek J, Koprivčić I, Babić M. Breast cancer in young women: pathologic and immunohistochemical features. Acta Clin Croat. 2018 Sep;57(3):497-502. https://doi.org/10.20471/acc.2018.57.03.13
8. Ehinger A, Malmström P, Bendahl PO, Elston CW, Falck AK, Forsare C, et al.; South and South-East Swedish Breast Cancer Groups. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta Oncol. 2017 Jan;56(1):68-74. PMID: 27762648. https://doi.org/10.1080/0284186X.2016.1237778
9. Volos LI, Dudash AP. Osoblyvosti ekspresiyi SOKh-2 v riznykh molekulyarnykh pidtypakh invazyvnoho protokovoho raku hrudnoi zalozy [Features of the COX-2 Expression in Different Molecular Subtypes of Invasive Ductal Breast Cancer]. Ukr ž med bìol sportu. 2022;1(35):68-78. https://doi.org/10.26693/jmbs07.01.068
10. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al. E-Cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991;113:173-85. PMID: 2007622. PMCID: PMC2288921. https://doi.org/10.1083/jcb.113.1.173
11. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta. 2012;1826:297-11. PMID: 22613680. https://doi.org/10.1016/j.bbcan.2012.05.002
12. Sethi S, Sarkar FH, Ahmed Q, Bandyopadhyay S, Nahleh ZA, Semaan A, et al. Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol. 2011;4:212-16. PMID: 21804917. PMCID: PMC3140009. https://doi.org/10.1593/tlo.10244
13. Saadatmand EM, Kruijf EM, Sajet A, Dekker-Ensink NG, van Nes JG, Putter H, et al. Expression of cell adhesion molecules and prognosis in breast cancer. Br J Surg. 2013;100:252-60. PMID: 23175431. https://doi.org/10.1002/bjs.8980
14. Zeisberg M, Neilson EG. Biomarkers of epithelial-mesenchymal transitions. J Clin Investig. 2009;119(6):1429-37. PMID: 19487819. PMCID: PMC2689132. https://doi.org/10.1172/JCI36183
15. Wells A, Chao YL, Grahovac J, Wu Q, Lauffenburger DA. Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci (Landmark Ed). 2011;16:815-37. PMID: 21196205. PMCID: PMC4003907. https://doi.org/10.2741/3722
16. Pecina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 2003;3(1):17. PMID: 14613514. PMCID: PMC270068. https://doi.org/10.1186/1475-2867-3-17
17. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003; 5:217-22. PMID: 14580257. PMCID: PMC314411. https://doi.org/10.1186/bcr651
18. Chand P, Garg A, Singla V, Rani N. Evaluation of immunohistochemical profile of breast cancer for prognostics and therapeutic use. Niger J Surg. 2018 Jul-Dec;24(2):100-106. PMID: 30283220. PMCID: PMC6158994. https://doi.org/10.4103/njs.NJS_2_18
19. Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020 Aug;77(2):181-185. PMID: 32056259. https://doi.org/10.1111/his.14091
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10. PMID: 1757079. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x
21. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al; Panel Members. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug;26(8):1533-46. PMID: 25939896. PMCID: PMC4511219. https://doi.org/10.1093/annonc/mdv221
22. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020 May;144(5):545-63. PMID: 31928354. https://doi.org/10.5858/arpa.2019-0904-SA
23. Qureshi HS, Linden MD, Divine G and Raju UB: E-Cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters. Am J Clin Pathol. 2006; 125(3): 377-85. PMID: 16613340. https://doi.org/10.1309/WMX7DRWTFVQP2LQT
24. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271-89. PMID: 27253694. https://doi.org/10.3322/caac.21349
25. Volos LI, Dudash AP. Тumor-infiltrating lymphocytes in nonluminal invasive ductal breast carcinoma. Azerbaijan Med J. 2022;1:131-37. https://doi.org/10.34921/amj.2022.1.021
26. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China 2015. CA Cancer J Clin. 2016;66:115-32. PMID: 26808342. https://doi.org/10.3322/caac.21338
27. Li DM, Feng YM. Signaling mechanism of cell adhesion molecules in breast cancer metastasis: Potential therapeutic targets. Breast Cancer Res Treat. 2011;128:7-21. PMID: 21499686. https://doi.org/10.1007/s10549-011-1499-x
28. Mareel M, Van Roy F. The human E-cadherin/catenin complex: a potent invasion and tumor suppressor. Verh K Acad Geneeskd Belg.1998;60:567-98.
29. Nollet F, Berx G, van Roy F. The role of the E-cadherin/ catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun. 1999;2:77-85. PMID: 10542129. https://doi.org/10.1006/mcbr.1999.0155
30. Yoshida R, Kimura N, Harada Y, Ohuchi N. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol. 2001;18:513-20. PMID: 11179480. https://doi.org/10.3892/ijo.18.3.513
31. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, et al. Epithelial E and P cadherins: Role and clinical significance in cancer. Biochim Biophys Acta. 2012;1826:297-311. PMID: 22613680. https://doi.org/10.1016/j.bbcan.2012.05.002
32. Wendt MK, Taylor MA, Schiemann BJ, Schiemann WP. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breastcancer. Mol Biol Cell. 2011;22:2423-35. PMID: 21613543. PMCID: PMC3135469. https://doi.org/10.1091/mbc.E11-04-0306
33. Romaniuk A, Lyndin M, Sikora V, Lyndina Y, Panasovska K. Histological and immunohistochemical features of medullary breast cancer. Folia Med Cracov. 2015;55(2):41-8. PMID: 26839242
34. Gould Rothberg BE, Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta - analysis. Breast Cancer Res Treat. 2006;100(2):139-48. PMID: 16791476. https://doi.org/10.1007/s10549-006-9248-2
35. Chekhun S, Bezdenezhnykh N, Shvets J, Lukianova N: Expression of biomarkers related to cell adhesion, metastasis and invasion of breast cancer cell lines of different molecular subtype. Exp Oncol. 2013;35(3):174-79. PMID: 24084454
36. Tang D, Xu S, Zhang Q, Zhao W. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol. 2012;29(2):526-33. PMID: 21519872. https://doi.org/10.1007/s12032-011-9948-2